Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT05682742
Active, not recruiting Not applicable

Clinical Investigation of the da Vinci Surgical System

NCT05682742 · tracked via the Priya Life Science USA tracker
Sponsor
Intuitive Surgical
Phase
Not applicable
Started
2022-12-12
Last updated
2024-06-03

Condition(s) studied

ThymomaMediastinal TumorGynecologic DiseaseGynecologic CancerPelvic Organ ProlapseProstate DiseaseProstate CancerInguinal HerniaVentral HerniaObesity, Morbid

Investigational drug(s) / intervention(s)

Robotic-assisted Surgery

Robotic-assisted Surgery: Subjects scheduled to undergo robotic-assisted surgery

Study summary

This prospective, multicenter, single-arm study is being conducted to confirm safety, effectiveness, and usability of da Vinci Surgical System in performing robotic-assisted surgical procedures.

Eligibility

Sex
ALL
Min age
21 Years
Max age
—
Healthy volunteers
No
Pre-operative Inclusion Criteria: * Age 21 years or older * Per study Investigator's discretion, subject is a suitable candidate to undergo multiport robotic-assisted surgery for the study specified procedure as a primary procedure Pre-operative Exclusion Criteria: * Subject is pregnant or suspected to be pregnant or breastfeeding * Subject has any other condition or personal circumstance that, in the judgment of the Investigator, might interfere with the collection of complete quality data * Subject is currently participating in or has participated in a study of an investigational agent or a significant risk investigational device study within the past 6 months * Subject belongs to vulnerable population. * Subject is contraindicated for anesthesia or surgery * Subject has had previous neoadjuvant therapy, previous chemotherapy, immunotherapy, and/or radiation therapy for treatment of the cancer to be resected within the past 6 months

Primary outcome measure(s)

  • Incidence of conversion — Intra-operative
    Effectiveness defined as the ability to complete the planned da Vinci robotic-assisted procedures without conversion to open.

Trial sites (4)

FacilityCityRegionStatus
Orlando Health, Inc. Orlando Florida
Sparrow Health System Lansing Michigan
The Valley Hospital Ridgewood New Jersey
The Ohio State University Wexner Medical Center Columbus Ohio

More Intuitive Surgical trials in the USA

da Vinci SP® Investigational Device Exemption Study in Colorectal Procedures Active, not recruiting
IS-001 Injection in Patients Undergoing Robotic-Assisted Colorectal Surgery Recruiting
Robotic vs. Open NSM for Early Stage Breast Cancer Active, not recruiting
Real World Registry for Use of the Ion Endoluminal System Active, not recruiting
Retrospective Acute Care Appendectomy Study Active, not recruiting

Other trials for the same condition

AFFIX: Post-market Study of MaxTack™ Motorized Fixation Device in Subjects Undergoing Ventral Hernia Repair Active, not recruiting
Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms Active, not recruiting
Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer Active, not recruiting
Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer Recruiting
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05682742 on ClinicalTrials.gov ↗ ← All trials in the USA